Applied Molecular Transport, Inc. (AMTI)

NASDAQ: AMTI · IEX Real-Time Price · USD
0.973
-0.006 (-0.65%)
Sep 30, 2022 4:00 PM EDT - Market closed
-0.65%
Market Cap 37.86M
Revenue (ttm) n/a
Net Income (ttm) -134.72M
Shares Out 38.90M
EPS (ttm) -3.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 112,161
Open 0.931
Previous Close 0.980
Day's Range 0.910 - 1.050
52-Week Range 0.850 - 26.440
Beta 1.30
Analysts Buy
Price Target 12.50 (+1,184.4%)
Earnings Date Nov 8, 2022

About AMTI

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Ph... [Read more...]

Industry Biotechnology
IPO Date Jun 5, 2020
Employees 125
Stock Exchange NASDAQ
Ticker Symbol AMTI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for AMTI stock is "Buy." The 12-month stock price forecast is 12.5, which is an increase of 1,184.42% from the latest price.

Price Target
$12.5
(1,184.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. ...

New York, New York--(Newsfile Corp. - July 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NASDAQ: AM...

2 months ago - Newsfile Corp

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses...

Los Angeles, California--(Newsfile Corp. - July 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applie...

2 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Applied Molecular Transport Inc. ...

New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NYSE: AMTI...

2 months ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $10...

Los Angeles, California--(Newsfile Corp. - July 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applie...

2 months ago - Newsfile Corp

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

2 months ago - Business Wire

Applied Molecular Shares Tumble After Disappointing Data From Mid-Stage Ulcerative Colitis Study

Applied Molecular Transport Inc (NASDAQ: AMTI) has announced topline Phase 2 results from the MARKET combination trial for AMT-101 in ulcerative colitis (UC).  In the MARKET trial, patients received eit...

2 months ago - Benzinga

Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patie...

Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

2 months ago - GlobeNewsWire

Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs

Applied Molecular Transport Inc (NASDAQ: AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development.  It is preparing for the end of Phase 2 meetings with the FDA to advance A...

4 months ago - Benzinga

Applied Molecular Transport Provides Strategy Update

Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis

4 months ago - GlobeNewsWire

Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis

4 months ago - GlobeNewsWire

Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D....

4 months ago - GlobeNewsWire

Applied Molecular's AMT-101 Shows Favorable Clinical Activity, Safety Profile In Inflammatory Bowel Disease

Applied Molecular Transport Inc (NASDAQ: AMTI) announced Phase 2 topline results from the FILLMORE monotherapy trial for AMT-101 in chronic pouchitis. Pouchitis is inflammation in the lining of a pouch ...

5 months ago - Benzinga

Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patien...

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD) –  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerat...

5 months ago - GlobeNewsWire

Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with C...

- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

5 months ago - GlobeNewsWire

Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company's Prop...

Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company's proprietary biologic product candidates to cross int...

5 months ago - GlobeNewsWire

Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Aff...

Company continues to strengthen key functions and corporate leadership

6 months ago - GlobeNewsWire

Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as follows

7 months ago - GlobeNewsWire

Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D...

7 months ago - GlobeNewsWire

Applied Molecular Transport Announces Board Appointments

John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair

8 months ago - GlobeNewsWire

Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021

Management to highlight novel oral biologics technology platform, clinical programs and research activities

11 months ago - GlobeNewsWire

Applied Molecular Transport Announces Upcoming Investor Events in September and October

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will p...

1 year ago - GlobeNewsWire

Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly...

1 year ago - GlobeNewsWire

Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance

1 year ago - GlobeNewsWire

Applied Molecular Transport to Present at Canaccord Genuity's 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D...

1 year ago - GlobeNewsWire